![]() ![]() ![]() Prior to further confirming the effects of T2DM on BM-MSC biology, future work with a larger cohort focusing on patients with different T2DM history is needed to understand the mechanism underlying our observation.” “Our data suggest that autologous administration of BM-MSCs in the treatment of T2DM should be performed in patients with T2DM duration <10 years and no obesity. T2DM duration directly altered the proliferation rate of BM-MSCs, abrogated the glycolysis and mitochondria respiration of BM-MSCs, and induced the accumulation of mitochondria DNA mutation. Short-term therapeutic effects were observed in patients with T2DM duration of <10 years and a body mass index <23, which is in line with the phenotypic analysis of the autologous BM-MSC population. Our data indicated that autologous BM-MSC administration was well tolerated in 30 T2DM patients. ![]() The safety was assessed in all the treated patients, and the efficacy was evaluated based on the absolute changes in the hemoglobin A1c, fasting blood glucose, and C-peptide levels throughout the 12-month follow-up. ”T2DM patients were enrolled, randomly assigned (1:1) by a computer-based system into the intravenous and dorsal pancreatic arterial groups. The purpose of this study was to test the hypothesis that autologous BM-MSC administration in T2DM patient is safe, and that the efficacy of the treatment is dependent on the quality of the autologous BM-MSC population and administration routes,” write the investigators. “Human bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) represent promising stem cell therapy for the treatment of type 2 diabetes mellitus (T2DM), but the results of autologous BM-MSC administration in T2DM patients are contradictory. No significant problems were detected in the patients’ health as a result of the treatment, and they appeared to benefit equally from both infusion methods. Researchers monitored the patients for 48 hours and re-examined them at one-month, three-month, six-month, and one-year intervals. Each received two infusions of the cells intravenously or by injection into an artery that supplies blood to the pancreas. A total of 30 adult patients with different body mass indexes whose Type 2 diabetes histories varied from one to 25 years were recruited for the study. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |